Prostate Cancer - Results from #80

Fast prostate MRI vs. conventional multiparametric prostate MRI: comparison and outcomes. April 9, 2025

The association between statin use, genetic variation, and prostate cancer risk. April 9, 2025

Mind matters: how anxiety and depression shape low-risk prostate cancer active surveillance adherence in a real-world population. April 9, 2025

Cancer-control outcomes of Radium- 223-pretreated lutetium- 177-PSMA Radioligand vs. Radium- 223-naïve mCRPC patients. April 9, 2025

Urologists' Estimation of Online Support Group Utilization Behavior of Their Patients With Newly Diagnosed Nonmetastatic Prostate Cancer in Germany: Predefined Secondary Analysis of a Randomized Controlled Trial. April 9, 2025

Accuracy is Key: Transrectal Ultrasound Versus Magnetic Resonance Imaging to Determine Prostatic Volume. April 8, 2025

Men's experiences of the Swedish Organised Prostate Cancer Testing programme: a qualitative study. April 8, 2025

SpaceOAR hydrogel complications in prostate cancer radiotherapy: a pictorial review. April 8, 2025

First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placeb April 8, 2025

First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial. April 8, 2025

Study of persistence and adherence to ADT in prostate cancer: relugolix, degarelix, and GnRH agonists in the US. April 8, 2025

New Study Published in Clinical Cancer Research Validates PROSTOX ultra Diagnostic Test for Predicting Radiation-Induced Late Toxicity in Prostate Cancer April 7, 2025

Validation and Derivation of MicroRNA-based Germline Signatures Predicting Radiation Toxicity in Prostate Cancer April 7, 2025

Real-world utilization patterns and survival in men with metastatic prostate cancer treated with Radium-223 in the United States. April 7, 2025

Identifying Patients at Risk of Early Lethal Prostate Cancer by Integrating Family History, Polygenic Risk Score, Rare Variants in DNA Repair Genes, and Lifestyle Factors. April 7, 2025

A Randomized Comparison of High Dose Rate and Low Dose Rate Prostate Brachytherapy Combined with External Beam Radiotherapy for Unfavourable Prostate Cancer: Efficacy Results after Median Follow-up 74 Months. April 7, 2025

Long-term outcomes of PSMA PET/CT-guided radiotherapy in biochemical failure patients post-radical prostatectomy: a 5-year follow-up analysis. April 7, 2025

Impact of obesity on prostatectomy outcomes: Insights from a large prospectively maintained cohort. April 7, 2025

Detection of MRI-Invisible Disease Using PSMA PET/CT in a Patient Considering Focal Therapy. April 4, 2025

LHRH Antagonists Restore Serum Testosterone Faster Than LHRH Agonists in Prostate Cancer Patients After Radiotherapy. April 4, 2025

Page 5 of 1474